StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report report published on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, February 26th.

Minerva Neurosciences Price Performance

NASDAQ:NERV opened at $1.58 on Friday. Minerva Neurosciences has a fifty-two week low of $1.42 and a fifty-two week high of $3.69. The stock’s 50-day moving average is $2.12 and its two-hundred day moving average is $2.36. The stock has a market cap of $11.05 million, a PE ratio of -3.59 and a beta of 0.12.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.49. On average, equities research analysts anticipate that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Northern Trust Corp lifted its position in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 36,878 shares of the biopharmaceutical company’s stock after buying an additional 13,829 shares during the quarter. Northern Trust Corp owned about 0.53% of Minerva Neurosciences worth $82,000 as of its most recent filing with the SEC. Institutional investors own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.